Evidence map›Paper›PMID 29638206›Full record

ArticleJournal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research2018

Development of a Validated Interferon Score Using NanoString Technology.

Hanna Kim, Adriana A de Jesus, Stephen R Brooks, Yin Liu, Yan Huang, Rachel VanTries, Gina A Montealegre Sanchez, Yaron Rotman, Massimo Gadina, Raphaela Goldbach-Mansky

Abstract read
In one paragraph

Article in Journal of interferon & cytokine research : the official journal of the International Society for Interferon and Cytokine Research, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 103 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
103citing papers in PubMed, 3 pooled it
6.7field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

103 citing papers in PubMed, 3 syntheses or guidelines pooled it, 180 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Anifrolumab Treatment in Cutaneous Lupus Erythematosus with and without systemic involvement: A Retrospective Study.Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

43 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Hanna Kim1 Lawrence Shulman Scholar, Office of the Clinical Director, and Pediatric Translational Research Branch, NIAMS, NIH , Bethesda, Maryland.
Adriana A de Jesus2 Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH , Bethesda, Maryland.
Stephen R Brooks3 Biodata Mining and Discovery Section, Office of Science and Technology, NIAMS, NIH , Bethesda, Maryland.
Yin Liu4 Extramural Program, NIAMS, NIH , Bethesda, Maryland.
Yan Huang2 Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH , Bethesda, Maryland.
Rachel VanTries2 Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH , Bethesda, Maryland.
Gina A Montealegre Sanchez2 Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH , Bethesda, Maryland.
Yaron Rotman5 Liver & Energy Metabolism Unit, Liver Diseases Branch, NIDDK, NIH , Bethesda, Maryland.
Massimo Gadina6 Translational Immunology Section, Office of Science and Technology, NIAMS, NIH, Bethesda, Maryland.
Raphaela Goldbach-Mansky2 Translational Autoinflammatory Disease Studies (TADS), NIAID, NIH , Bethesda, Maryland.
National Institutes of Health · USOffice of Science · USOffice of Extramural Research · USOffice of the Director · US

Funding

Translational Immunology research: a support for clinical immunological researchZICAR041181 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI GADINA, MASSIMO · 2009 to 2025
$31.5M
Pathogenesis, and Outcome of Autoinflammatory Diseases, NOMID/CAPS, DIRA, CANDLE, SAVI, NLRC4-MAS, Stills-like Diseases, and other Undifferentiated Autoinflammatory DiseasesZIAAI001220 · NIAID · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · PI GOLDBACH-MANSKY, RAPHAELA · 2017 to 2025
$22.3M
Applying Bioinformatics to Research in Immune, Muscle, and Bone DiseasesZIHAR041173 · NIAMS · NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES · PI GADINA, MASSIMO · 2009 to 2020
$11.0M
6 · The paper itself

Abstract

Chronic elevation of interferon (IFN)-response genes (IRG) in a subset of patients with systemic immune-dysregulatory diseases, including the Mendelian Type-I IFN-mediated autoinflammatory diseases and some autoimmune diseases suggest a causative role of excessive IFN signaling in the disease pathogenesis and as target for treatment. We developed a 28-IFN response gene scoring system to calculate either a standardized or geomean score by customizing a NanoString assay to quantify the expression of putative IRGs. The gene targets were selected in patients with the IFN-mediated disease chronic atypical neutrophilic dermatosis with lipodystrophy and elevated temperature (CANDLE) and an adult patient with chronic hepatitis C who received the first dose of pegylated interferon alpha-2a. The putative target genes were validated in patients with STING-associated vasculopathy with onset in infancy (SAVI), a monogenic autoinflammatory disease caused by gain-of-function mutations in TMEM173 that encodes the viral sensor stimulator of IFN genes (STING), and had low expression in clinically active patients with the monogenic IL-1-mediated autoinflammatory disease, neonatal-onset multisystem inflammatory disease (NOMID) and in healthy controls. The score calculation on the NanoString assay is rapid and showed high reproducibility and low intra-, and interassay variability. The utility of this 28-gene IFN score may be explored in the diagnosis of patients with presumed interferonopathies and as a biomarker to assess disease activity, long-term outcome, and treatment responses.

Indexed as

Nucleic Acid Amplification TechniquesAdolescentAdultAutoimmune DiseasesBiomarkersChildChild, PreschoolFemaleHumansInfantInterferonsMaleMiddle AgedReproducibility of ResultsYoung AdultBiomarkersInterferonsassay validationblood IFN signatureIFN-mediated autoinflammatory diseasesIFN scoreinterferonopathiesNanoString assay

Identifiers

PMID29638206
PMCPMC5963606
OpenAlexW2796690375

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.